Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the best performers on the stock market today. At current price of $10.82, the shares have already added 0.35 points (3.39% higher) from its previous close of $10.47. Should you buy or avoid them? The stock sets an active trading volume day with a reported 318097 contracts so far this session. CYTK shares had a relatively better volume day versus average trading capacity of 656.03 thousand shares, but with a 53.67 million float and a 3.56% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for CYTK stock indicates that the average analyst price target is $14.33 per share. This means the stock has a potential increase of 32.44% from where the CYTK share price has been trading recently which is between $10.22 and $10.63. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $10.
The shorts are climbing into Cytokinetics, Incorporated (CYTK) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a rise in short interest in CYTK shares. While short interest still represents only 7.44% of CYTK’s float, the number of shares shorted have risen by 529110. The number of shares shorted advanced to 3993653 shares, up from 3464543 shares during the preceding fortnight. With average daily trading volumes at 494452 shares, days to cover increased to about 5.995098 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Edited Transcript of CYTK earnings conference call or presentation 9-May-19 8:30pm GMT” and dated May 09, 2019.
During the recent trading session for Cytokinetics, Incorporated (NASDAQ:CYTK), the company witnessed their stock rise $0.35 over a week and surge $1.82 from the price 20 days ago. When compared to their established 52-week high of $11.33, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 05/16/19. The recent low of $5.75 stood for a -4.46% since 03/07/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.91 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Cytokinetics, Incorporated, the two-week RSI stands at 67.56. This figure suggests that CYTK stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current CYTK readings is similarly very revealing as it has a stochastic reading of 78.24% at this stage. This figure means that CYTK share price today is being oversold.
Technical chart claims that Cytokinetics, Incorporated (CYTK) would settle between $10.66/share to $10.85/share level. However, if the stock price goes below the $10.25 mark, then the market for Cytokinetics, Incorporated becomes much weaker. If that happens, the stock price might even plunge as low as $10.03 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.25. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Cantor Fitzgerald, assumed coverage of CYTK assigning Overweight rating, according to their opinion released on September 21. Morgan Stanley, analysts launched coverage of Cytokinetics, Incorporated (NASDAQ:CYTK) stock with a Equal-Weight recommendation, according to their flash note issued to investors on September 10. Analysts at Morgan Stanley are sticking to their Overweight stance. However, on November 22, they lifted price target for these shares to $17 from $25.
CYTK equity has an average rating of 2.33, with the figure leaning towards a bullish end. 6 analysts who tracked the company were contacted by Reuters. Amongst them, 2 rated the stock as a hold while the remaining 4 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 4 analysts rated Cytokinetics, Incorporated (NASDAQ:CYTK) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, CYTK stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 8.37 while for the average stock in the same group, the multiple is 49.5.
Cytokinetics, Incorporated (CYTK)’s current-quarter revenues are projected to climb by nearly 9.41% to hit $6.81 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 4.19% from $31.5 million to a noteworthy $32.82 million. At the other end of the current quarter income statement, Cytokinetics, Incorporated is expected to see its adjusted earnings surge by roughly -3.92% to hit $-0.53 per share. For the fiscal year, CYTK’s earnings are projected to climb by roughly 5.13% to hit $-1.85 per share.